A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

Daniel S. Lenchner(Yale Cancer Center), Frederick H. Wilson(Yale Cancer Center)
npj Precision Oncology
January 5, 2024
Cited by 4


Related Papers